

Announcement Summary

Entity name

AUSTRALIAN CLINICAL LABS LIMITED

Date of this announcement

Friday July 16, 2021

The +securities the subject of this notification are:

€ +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
ACLAL	PERFORMANCE RIGHTS	104,025	13/07/2021

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

AUSTRALIAN CLINICAL LABS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

Registration number

ABN

94645711128

1.3 ASX issuer code

ACL

1.4 The announcement is

☑ New announcement

1.5 Date of this announcement

16/7/2021



Part 2 - Issue details

- 2.1 The +securities the subject of this notification are:
- € +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX
- 2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

☑ has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

ACLAL: PERFORMANCE RIGHTS

Date the +securities the subject of this notification were issued

13/7/2021

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?
⊗ No

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

The full terms and conditions of the ACL LTVR Plan were released to the ASX Market Announcements Platform on 14 May 2021 (available at https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02374681-2A12 98171?access_token=83ff96335c2d45a094df02a206a39ff4).

The terms and conditions of the ACL LTVR Plan were outlined in section 6.6.1 of the prospectus lodged by ACL and ACL SaleCo Limited (ACN 648 177 646) with the Australian Securities and Investment Commission on 28 April 2021 and released to the ASX Market Announcements Platform on 14 May 2021 (available at https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02374646-2A1298149?access token=83ff96335c2d45a094df02a206a39ff4).

Any other information the entity wishes to provide about the +securities the subject of this notification

Issue details

Number of +securities

104,025



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

ASX +security code and description

Total number of +securities on issue

ACL: ORDINARY FULLY PAID 201,834,015

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description

Total number of +securities on issue

ACLAL: PERFORMANCE RIGHTS 908,557



Part 5 - Other Listing Rule requirements

- 5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?
 ☑ Yes
- 5.1a Select the number of the applicable exception in Listing Rule 7.2

13